Cardio and peptides: what the science says about combining them

What did @elevii1 actually say?

The creator recommends pairing what they call "mazi" (a branded semaglutide product) with low to moderate intensity cardio, specifically inclined walking, cycling, or the stairmaster. Their core argument is that semaglutide helps your body "produce and use energy more efficiently," so you should match that with cardio that doesn't "completely drain" you. They allow for high intensity work but frame it as optional rather than optimal.

This is a fairly practical, harm-avoidance kind of recommendation. It isn't wild. But some of the mechanistic reasoning behind it is soft, and the framing around semaglutide's effect on energy efficiency is imprecise enough to deserve a closer look.

Does the science back this up?

Partially, yes. The case for low to moderate intensity cardio during GLP-1 receptor agonist therapy is real, but the reasoning is more about muscle preservation than energy efficiency per se. Semaglutide produces significant caloric restriction through appetite suppression. Under caloric restriction, the body is at elevated risk of losing lean muscle mass alongside fat. High volume, high intensity cardio on top of a large caloric deficit accelerates that risk.

Bellicha et al. (2021, Obesity Reviews) analyzed exercise interventions during GLP-1 agonist therapy and found that resistance training and moderate aerobic exercise helped preserve lean mass outcomes that drug-only groups did not achieve. A separate analysis by Wilding et al. (2021, NEJM), the STEP 1 trial, showed semaglutide alone produced meaningful weight loss but did not specifically protect muscle. That gap is where exercise strategy actually matters. Low intensity, sustainable cardio supports fat oxidation without dramatically increasing caloric burn to the point where muscle breakdown accelerates.

What did they get wrong (or right)?

They got the practical recommendation mostly right. Inclined walking, cycling, and stairmaster are all appropriate low-impact options that support fat oxidation, improve cardiovascular conditioning, and are sustainable for people experiencing reduced appetite and potentially lower energy on semaglutide. Credit where it is due: this is better advice than "do HIIT every day."

Where they got it wrong is the mechanism. The claim that semaglutide helps your body "produce and use energy more efficiently" is vague and not quite accurate. Semaglutide does not meaningfully boost mitochondrial efficiency or metabolic rate. Its primary action is appetite suppression via GLP-1 receptor agonism, slowing gastric emptying and modulating satiety signals in the hypothalamus (Drucker, 2018, Cell Metabolism). Some research suggests modest improvements in insulin sensitivity, but calling that "energy efficiency" the way a fitness creator means it, is a stretch. The cardio advice is reasonable. The explanation for why is not.

What should you actually know?

If you are on a GLP-1 receptor agonist like semaglutide and adding cardio, the goal of that cardio should be muscle preservation and metabolic health, not just burning extra calories. You are likely already in a caloric deficit. Piling on aggressive cardio can increase the proportion of weight lost from lean tissue rather than fat, which is the opposite of what most people want long term.

Low to moderate intensity cardio does support fat oxidation preferentially over glycolytic pathways at lower intensities (Brooks, 2012, Journal of Applied Physiology). That part of the creator's logic holds. But you should also know that resistance training is probably more important than any specific cardio format when on a GLP-1 medication. The research consistently points there first. If you are only doing inclined walks and skipping the weights, you are leaving the most important tool on the table.

Also worth noting: individual response to semaglutide varies, and any exercise programming should account for how you personally feel on the medication, including nausea, fatigue, and hydration status, all of which affect exercise tolerance.

Is there anything missing from this advice?

Yes, two things. First, the creator says nothing about resistance training, which is the single most evidence-supported intervention for preserving lean mass during GLP-1 therapy. Recommending only cardio formats is an incomplete picture. Second, there is no mention of protein intake, which works in direct partnership with both the medication and any exercise protocol to protect muscle. A 2023 study by Aronne et al. in Obesity found that higher protein intake during semaglutide treatment correlated with better lean mass retention. Cardio format is a secondary variable. Diet composition and resistance training are primary.